Satellos Granted Composition of Matter Patent for Forazapadin
Composition of matter provides U.S. protection through Sept. 6, 2044, as forazapadin advances in Phase 2 development TORONTO, Oct. 05, 2026 (GLOBE NEWSWIRE) — Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced that the United States Patent and Trademark Office […]